| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Andrology (K.A.W., C.M.A., M.J., P.R.L., D.J.H.), ANZAC Research Institute, Concord Hospital, University of Sydney, New South Wales 2139, Australia; Department of Medicine (R.A.D., J.D.Z.), University of Melbourne, Austin Health, Heidelberg 3084, Victoria, Australia; and Department of Reproductive Medicine (P.I.), Westmead Hospital, New South Wales 2145, Australia
Address all correspondence and requests for reprints to: Professor David J. Handelsman, ANZAC Research Institute, Department of Andrology, Sydney, New South Wales 2139, Australia. E-mail: djh{at}anzac.edu.au.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Although androgens are obligatory precursors for conversion to estrogens by aromatase (7), the importance and exact function(s) of additional direct effects of androgens mediated via genomic AR or nongenomic mechanisms on follicle or oocyte development and function remain unclear. However, AR-mediated actions within the ovary are thought to play important roles because androgens have been indicated as directly augmenting FSH signaling via a post-cAMP mechanism (8). The direct actions of androgens via ARs is supported by the universality of AR expression in mammalian ovaries such as in rodents (9, 10), domestic species (11, 12), and primates (13, 14). In rat and primate ovaries (14, 15, 16), AR is predominantly expressed in granulosa cells, with expression being highest in preantral/early antral follicles and gradually decreasing as the follicles mature (16, 17). Nevertheless, in vitro and in vivo investigations into the direct effect of androgens on follicular development have given conflicting findings showing inhibition of follicular development and increased granulosa apoptosis (18), modulation of gonadotrophin-stimulated ovarian function (19), antagonism of antiapoptotic effects of estradiol (E2) (20), but also stimulation of follicle growth and survival in primate (21, 22) or mouse (23) and IGF paracrine mechanisms during follicle growth (24). Furthermore, AR is known to be expressed in the brain and regulated by testosterone and estradiol (25). Hence, AR signaling has the potential to influence feedback mechanisms regulating the hypothalamic GnRH and pituitary LH and FSH release, including the ovulatory LH surge.
Development of genetic models of androgen insensitivity created by functional inactivation of the AR in females, allows in vivo investigation of the roles of AR mediated actions on reproductive function. However, because the AR gene is encoded on the X chromosome and hemizygous males with an inactive AR (the classical tfm mouse phenotype) are sterile, homozygous AR null females cannot be produced by natural mating. The first experimental model for female androgen insensitivity was created by breeding males chimeric for the tfm gene with female mice heterozygote for the tfm mutation to produce homozygous Tfm/Tfm female mice (26). These mice exhibited increased follicle atresia and reduced follicle numbers, but AR-mediated androgen action was not absolutely essential for ovulation, mating, pregnancy, or lactation (26, 27). More recently, using the Cre/LoxP system, female mice homozygous for deletion of the AR protein due to deletion of exon 1 (28) or 2 (29, 30) and insertion of a premature stop codon have been reported. In these models in which there is either no or a severely truncated AR protein produced, AR/ female mice remain fertile with fewer pups per litter and increased follicular atresia (28, 29, 30). Moreover, follicle development was reportedly unaffected in young (up to 16 wk of age) AR/ mice (28, 29), but older females exhibited accelerated follicle depletion, which led to a total loss of follicles at 40 wk of age (28). However, although gene alterations likely to impact follicle development were highlighted (28), the definitive mechanism of the subfertility at younger ages was not defined despite severe and accelerated age-related follicle depletion.
In the present study, homozygous AR/ female mice were generated using Cre/LoxP recombination for an in-frame excision of exon 3, encoding the second zinc finger essential for DNA-binding. Exon 3 of the AR gene was targeted because this encoding region is highly conserved among species (31), and several independent spontaneous mutational deletions in humans all produced complete androgen insensitivity syndrome (32, 34), a finding replicated in the mouse with this exon 3 deletion (31). (Also see the McGill University Androgen Receptor Gene Mutations Database at http://androgendb.mcgill.ca/.) Therefore, by the in-frame deletion of exon 3, the normal reading frame is retained allowing the protein produced to have seven of the eight exons intact, unlike previous AR/ studies (28, 29, 30) that deleted at least six exons. In vitro studies have revealed that the protein produced by point mutations or deletion in exon 3 has normal androgen binding affinity and is localized in the nucleus but has markedly reduced DNA-binding affinity and fails to activate transcription of an androgen-responsive reporter gene (32, 34, 35). Therefore, the exon 3 deleted mutant AR protein produced is nonfunctional as a nuclear transcription factor and can feasibly be held responsible for the results exhibited in this model. Hence, the present model provides a novel system for a detailed analysis of the direct effects of a deficiency in classical genomic AR signaling on female fertility and ovarian follicular growth and health. This study provides evidence that classical genomic AR mediated signaling plays important roles in regulating late stages of follicular development and in particular ovulation but is not necessary for preservation of ovarian follicle populations during aging.
| Materials and Methods |
|---|
|
|
|---|
Generation of AR knockout mice
Androgen receptor knockout mice (AR/) and heterozygous mice (AR+/) were generated by crossing ARflox mice [exon 3 flanked by loxP sites, as previously described (31)] with transgenic cytomegalovirus (CMV)-Cre mice as a universal deletor. Because the CMV-cre transgene (36) as well as the AR are both located on the X chromosome, a two-step breeding strategy was required. First, ARflox and CMV-cre mice were crossed to obtain heterozygous (AR+/) female offspring expressing CMV-cre. Second, these AR+/ females carrying CMV-cre were mated with males containing ARflox, with meiotic cross-over allowing production of females with complete homozygous knockout of the AR exon 3.
DNA and RNA extraction, genotyping, and RT-PCR
Genomic DNA isolated from toe clip or tail biopsy, as previously described (37), was used as a template for PCR genotyping to detect rearrangements in the mouse AR gene. Forward PCR primers upstream of the first LoxP site (ARExcised-forward, CAGAAATCCACCTGCCTCTACC), within mouse AR exon 3 (AREx3-forward, CTTCTCTCAGGGAAACAGAAGT) and within NEO cassette (ARNeo-forward, TAGATCTCTCGTGGGATCATTG) were used with a common reverse primer located within intron 3 (AR-reverse, GGGAGACACAGGATAGGAAATT) (Fig. 1A
). The conditions for the PCR were as follows: 94 C for 5 min followed by 39 cycles of 94 C for 1 min, 58 C for 1 min, 72 C for 1 min, and final extension at 72 C for 5 min. Mice containing the CMV-cre gene were detected using primers and PCR conditions as described (36). AR/ males and females were distinguished, using primers and PCR conditions for the mouse Y chromosome sry gene as previously described (31).
|
Quantitative real-time RT-PCR
Using real-time RT-PCR, mRNA expression for steroidogenic acute regulatory protein, P450side-chain cleavage, P450c17, and P450aromatase was carried out on ovaries collect after natural mating and the presence of a copulatory plug to evaluate possible impairments in steroidogenic enzymes. Ovaries collected at diestrus were assessed histologically for follicle health and gene expression was analyzed for B cell leukemia/lymphoma-2 (Bcl-2) (prosurvival) and Bcl-2-associated X protein (Bax) (proapoptotic). To assess whether the observed effects present in this model may be due to estrogenic effects mediated by 5
-androstandiols, mRNA expression for the following enzymes that carry out the conversion of androgens to estrogens were analyzed: 5
-reductase type I, 5
-reductase type II, 3ß-hydroxysteroid dehydrogenase (HSD), and 3
-HSD. Total RNA was extracted from whole ovaries from all genotypes [(diestrous samples (n = 6/genotype) and estrous samples (n = 5/genotype)] using TriReagent (Sigma, Castle Hill, Australia) according to the manufacturers protocol. Reverse transcription was performed with 2 µg of total RNA using SuperScript III first-strand synthesis system (Invitrogen). Quantitative RT-PCR analysis on resulting cDNA was performed in duplicate using Corbett RotorGene 2000 real-time amplification system (Corbett Research, Sydney, Australia). Specific commercially purchased SYBR Green primers were used with SYBR Green master mix (Superarray Bioscience Corp., Bethesda, MD). Mouse ribosomal protein was used as a housekeeping gene. There was no significant differences in mouse ribosomal protein mRNA levels between treatment groups (P > 0.05). Reaction steps were 15 min at 95 C, followed by 40 cycles of denaturation at 95 C for 30 sec, annealing at 55 C for 30 sec, and extension at 72 C for 30 sec. A standard curve was generated for each gene from five serial dilutions of purified PCR product. Standards were assigned an arbitrary value and mRNA expression determined relative to housekeeping gene expression in each sample. No template controls, substituting water for cDNA, and a negative reverse transcription were included in each run.
AR immunohistochemistry
Ovaries from 10- to 12-wk-old mice were collected, fixed in 4% paraformaldehyde, dehydrated in alcohols, cleared in xylene, embedded in paraffin, and serially sectioned (5 µm). Ovarian sections were subjected to microwave (600 W) antigen retrieval in 10 mM citrate buffer (pH 6.0) for 15 min. Endogenous peroxidase activity was blocked by incubating sections in 3% hydrogen peroxide for 5 min. To block nonspecific binding, sections were incubated in 1% BSA for 1 h at room temperature followed by goat serum for 30 min. Sections were then incubated with a polyclonal anti-AR antibody (N-20) (Santa Cruz Biotechnology, Santa Cruz, CA) (1:100 dilution) in 1% BSA/PBS for 1 h at 37 C. Negative controls were incubated with a control primary antibody (Santa Cruz rabbit IgG). Antibody binding was visualized using the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) followed by color development using liquid DAB+ (Dako, Botany, Australia), according to the manufacturers instructions. Sections were briefly counterstained with 0.5% Toludine Blue, dehydrated through ethanol series and xylene, and mounted.
Fertility
To estimate natural fertility 8- to 10-wk-old females [AR+/+ (n = 5), AR+/ (n = 8), and AR/ (n = 9)] were continuously mated with an individual ARflox male (at least 8 wk old) for a 10-month period. Cages were monitored daily and the number of pups and litters were recorded.
Classification and enumeration of follicles
The follicle classification system used was based on the system used by Myers et al. (38). Briefly, primordial consisted of an oocyte surrounded by flattened granulosa cells, primary consisted of an oocyte surrounded by one layer of cuboidal granulosa cells, small preantral contained an oocyte with 1.52 layers of cuboidal granulosa cells, large preantral were classified by having an oocyte surrounded by more than two and up to five layers of cuboidal granulosa cells, small antral contained an oocyte surrounded with more than five layers of cuboidal granulosa cells, and/or one or two small areas of follicular fluid whereas large antral contained a single large antral cavity, and preovulatory possessed a single large antrum and an oocyte surrounded by cumulus cells at the end of a stalk of mural granulosa cells. Corpus lutea (CL) were identified by morphological properties consistent with luteinized follicles and by being visible throughout several serial sections. Zona pellucida remnants (ZPRs) (representing end-stage atretic follicles) were defined as previously described (38).
One ovary per animal was collected from 10- to 12-, 26-, and 52-wk-old mice at diestrus, fixed, and then processed through graded alcohols into glycolmethacrylate resin (Technovit 7100; Heraeus Kulzer, Chatswood, Australia). Ovaries were serially sectioned at 20 µm, stained with periodic acid-Schiff, and counterstained with hematoxylin. Follicles were counted using a microscope (Olympus, Tokyo, Japan) with Stereo Investigator software (MicroBrightField, Williston, VT). Total number of growing follicles per ovary at different developmental stages for each of the genotypes (minimum three ovaries counted per genotype per time point) was determined as previously described (38). For all histological analysis, repetitive counting of follicles was avoided by counting/measuring only follicles containing an oocyte with a visible nucleolus. To avoid bias, all ovaries were analyzed without knowledge of genotype.
Measurement of follicular growth and health
One ovary per mouse was collected at diestrus from mice at 1012 wk of age, fixed, dehydrated in alcohols, cleared in xylene, embedded in paraffin, serially sectioned (5 µm), stained with hematoxylin and eosin or proliferating cell nuclear antigen (PCNA; minimum three ovaries/genotype), and every 10th section of each ovary was analyzed.
The growth rate of follicles was estimated by measuring diameters of all follicles, and their contained oocyte, in two perpendicular axes using a light microscope at x20, calibrated using Stereo Investigator computer software (MicroBrightfFeld). The mean diameter at each follicular (or oocyte) developmental stage was calculated.
Cellular proliferation in the ovary was estimated by PCNA staining using a commercially available kit (Zymed PCNA detection kit; Invitrogen) according to the manufacturers instructions. In all experiments mouse primary antibody isotype control (Invitrogen) as a negative control and mouse intestinal tissue as a positive control were run in parallel. Follicles were classified, as above and then granulosa cell nuclei within each follicle positively stained for PCNA (positive staining was defined as intense brown staining of the nucleus) were counted. The average percentage of proliferating granulosa cells for each follicular development stage/ovary, and similarly, the percentage of theca proliferating cells/ovary were calculated.
Unhealthy follicles at different developmental stages were classified according to strict morphometric criteria if they contained a degenerate oocyte, disorganized granulosa cell layers, and/or more than 10% of the granulosa cells being pyknotic in appearance as previously described (39). The proportion of unhealthy follicles per ovary was estimated as the percentage of all follicles.
Measurement of ovulation and oocyte viability
To quantify numbers of ovulated oocytes a minimum of six mice per genotype (68 wk old) were treated with 10 IU pregnant mare serum gonadotropin and 46 h later 10 IU pregnant mare serum gonadotropin (CenVet, Artarmon, New South Wales, Australia), mimicking an endogenous LH surge to induce ovulation. Ovulation was examined 16 h after human chorionic gonadotropin injection. Oocyte-cumulus complexes (OCCs) were collected from the oviducts and counted.
To evaluate in vivo fertilization after natural mating, 8-wk-old female mice (minimum of five per genotype) were housed with a known fertile wild-type (AR+/Y) male mouse. Cages were monitored daily, and on the identification of a copulatory plug, female mice were killed immediately, OCCs collected from the oviducts, counted, and placed in M2 medium (Sigma). Fertilization was identified by the extrusion of the second polar body before embryos were cultured overnight at 37 C with 5% CO2 in M16 medium (Sigma) to assess the number of embryos reaching cleavage to the two-cell stage.
Hormone assays
Serum samples (at least six per genotype and time point) for hormone assay were obtained at diestrus as determined by light microscopic analysis of vaginal epithelial cell smears collected daily in 20 µl of sterile PBS and then transferred to glass slides, air dried, and stained with 0.05% Trypan Blue.
Mouse serum FSH and LH were determined using species-specific immunofluorometric assays (DELFIA; PerkinElmer, Turku, Finland) as described previously (40, 41). Serum estradiol levels were measured by time-resolved immunofluorometric (DELFIA) and testosterone assays by in-house RIA in extracts of serum as described previously (42, 43) with detection limits of 20 pM and 0.1 nM and intraassay variability of 12.7 and 7.5% for estradiol and testosterone assays, respectively. Cross-reactivities for testosterone were: 5
-androstane-3ß-diol, 0.96%; 5
-androstane-3
-17ß-diol, 0.51%; androstanedione, 0.29%; androstenediol, 0.20%; dehydroisoandrostenne, 0.011%; cortisol, E2, androsterone, dehydroepiandrosterone sulfate, less than 0.009%. Estradiol cross-reactivities were: estrone, estrone-sulfate, estriol, 2-hydroxyestriol, 16-OxoE2, 16OH-estrone, E2-SO4, E-glucuronide, less than 1%; testosterone, progesterone, dehydroepiandrosterone, cortisol, less than 0.01%. Serum or ovarian homogenates were extracted with (1:100 volumes) diethyl ether for estradiol or hexane-ethyl acetate (3:2) for testosterone.
Ovaries were homogenized in 100 µl volume of PBS + 0.5% BSA and 0.5 mM EDTA buffer on ice using a pestle. Homogenates were extracted with 10 volumes of organic solvent (1000 µl of organic solvent per 100 µl of tissue homogenate), vortexed thoroughly for approximately 2 min and allowed to stand at 4 C for 1 h. Samples were then centrifuged for 10 min (4 C, 3000 rpm) before freezing the aqueous layer in a dry ice-ethanol mixture. The organic layer was removed into a clean glass test tube and dried overnight at 37 C. The extract was reconstituted in 100 µl of 1% gelatin PBS (pH 7.2) by thorough vortexing before reextraction by adding a further 1000 µl of organic solvent and repeating the extraction and drying procedure. The dried residue was then gently dissolved in 50 µl of estradiol or testosterone assay buffer, and the reconstituted extract was assayed as for the serum extracts (42, 43).
Statistical analysis
Statistical analysis was performed using NCSS 2004 software (NCSS Statistical Software, Kaysville, UT). Unless otherwise stated, all results were expressed as means ± SEM. Statistical differences were tested by ANOVA with post hoc test using Fishers least significant differences multiple-comparison test. All parametric tests were confirmed by nonparametric equivalent tests. The proportion of females to have produced their first litter and10th pup was analyzed by Fishers exact test, whereas the time in days each breeder took to produce their first litter and 10th pup was analyzed with the use of Kaplan-Meier analysis using log rank test to compare groups. P values smaller than 0.05 were considered statistically significant.
| Results |
|---|
|
|
|---|
Fertility of AR-deficient females
Litter size was markedly reduced by 60% in AR/ (3.2 ± 0.9 pups/litter) (P < 0.01), compared with AR+/+ (average 8.1 ± 0.4 pups/litter) and AR+/ (average 6.4 ± 0.6 pups/litter) breeders over a 10-month breeding trial (Fig. 2A
). AR/ female breeders also took longer to produce their first litter (median AR+/+ = 22 d, AR+/ = 21 d, and AR/ = 61 d, P < 0.05) (Fig. 2B
) with 30% of AR/ breeders never producing a litter. Moreover, both AR/ and AR+/ female breeders took longer than AR+/+ to produce 10 pups (median AR+/+ = 32 d, AR+/ = 73 d, and AR/ = 87 d, P < 0.01) (Fig. 2C
). There was no difference in the frequency of litters per month among the three genotypes.
|
Phenotype of AR-deficient females
Ovarian weights were significantly reduced by 23% in AR/ and 26% AR+/ female mice when compared with AR+/+ controls at 57 wk of age (P < 0.01) and 17% in both AR/ and AR+/ at 1012 wk of age (P < 0.01) but not at 26 or 52 wk of age (Fig. 3A
). Uterine and body weights did not differ according to genotype or age (data not shown). There was no overt effect of genotype on the macroscopic appearance of the ovaries and uterus. Furthermore, there was no difference in weights of somatic organs (kidney, heart, and liver) according to genotype or age nor among the AR+/+, AR+/, or AR/ genotypes (data not shown).
|
Effect of AR deficiency on hyperstimulated and natural ovulation, fertilization, and early embryo development
The number of oocytes collected from the oviducts of superovulated mice was significantly increased in AR+/ but did not differ between AR/ or AR+/+ genotypes (AR+/+: 29.5 ± 2.0; AR+/: 39.3 ± 3.3; AR/: 25.2 ± 4.1, P < 0.05) (Fig. 4A
).
|
Real-time RT-PCR on ovaries collected from mice that have naturally mated detected that aromatase expression was significantly decreased by 82% in AR+/ and 71% in AR/ ovaries, compared with AR+/+ ovaries (P < 0.05). There was no difference in expression levels of steroidogenic acute regulatory protein, P450scc, or P450c17 between genotypes (Fig. 4D
).
Effects of AR deficiency on serum FSH, LH E2, and testosterone (T) concentrations and intraovarian T and E2 levels
Levels of baseline serum FSH, LH, E2, and T were not significantly different among the three genotypes at 1012 and 26 wk of age at the diestrous stage of the estrous cycle (Fig. 5A
).
|
Using mRNA collected from the ovaries of mice at diestrous, real-time RT-PCR detected that there was no difference in expression levels of 5
-reductase type I, 5
-reductase type II, 3ß-HSD, or 3
-HSD between genotypes (Fig. 5C
).
Effect of AR genotype on follicle growth and health
To investigate possible abnormalities in follicle growth and somatic cell proliferation, oocyte and follicle diameters and PCNA immunohistochemistry were assessed. There were no significant differences between genotypes in oocyte (data not shown) and follicle diameters (Fig. 6A
) or granulosa or theca cell (data not shown) PCNA staining (Fig. 6B
) at any stage of follicle development.
|
ZPR numbers did not differ according to genotypes or age; however, ZPR numbers were nonsignificantly higher in the AR/ mouse ovaries at 26 week of age (AR+/+: 28.2 ± 12.8; AR+/: 66.8 ± 22.9; AR/: 206.6 ± 92, P = 0.09) (Fig. 6D
).
Real-time RT-PCR analysis using mRNA collected from the ovaries of mice at diestrus showed that between genotypes there was no difference in expression levels of Bax or Bcl2 (Fig. 6E
).
| Discussion |
|---|
|
|
|---|
and -ß receptors. In recent years, it has been identified that androgens also have additional direct effects mediated by the AR on follicle development and female fertility. The current study set out to selectively target classical genomic AR signaling pathways in vivo and investigate the importance of these AR-mediated actions on female fertility through effects on oocyte and follicular development and ovulation. AR/ mice were generated by an in-frame deletion of exon 3, which maintained the production of a largely intact AR protein, which is transcriptionally inactive and hence classically nonfunctional. Males hemizygous for this mutant AR confirmed the complete abolition of classic genomic AR function by exhibiting a classical tfm phenotype (31), similar to that observed in spontaneous (44) and targeted (30, 31) AR knockout models. The complete deletion of exon 3 of the AR in the ovaries of homozygous female (AR/) mice used in this study was confirmed by PCR, which detected only AR with excised exon 3 and no intact exon 3 in genomic DNA or RNA. In the present study, the observation that homozygous classical inactivation of the AR reduces but does not abolish female fertility is in agreement with previous studies (26, 28, 29). Our findings of a predominant defect in late follicle development and/or ovulation as the key mechanism(s) leading to the subfertility coupled with the novel finding that the reduction in fertility is without substantial loss in follicle populations, may also explain the previously observed reduced litter size in other studies of AR/ female mice produced either as embryonic chimeras (26) or major deletions in AR, resulting in production of no or extremely truncated AR protein (28, 29, 30). However, the relatively unaffected follicle development observed differs from the findings of an AR knockout model whereby the deletion within the AR gene results in no protein being produced, which reported that accelerated follicle depletion was the principal mechanism causing subfertility with age (28). By contrast, AR/ females maintaining the production of a transcriptional inactive AR protein in the present study produced an equally subfertile ovarian phenotype, but follicle populations remained undiminished with all follicular developmental stages present at 10 months of age.
The reduction in ovulation identified in the present and similar studies, by the reduction in CL numbers in AR/ (28, 29) and AR+/ ovaries and decrease in naturally ovulated oocytes collected from oviducts of AR/ females in this study, may be due to intrinsic defects within the ovary, such as reduced responsiveness of the follicle or an extrinsic defect in the hypothalamic-pituitary regulation of gonadotropin secretion. This extraovarian defect is supported by the observed reduction in aromatase expression, an FSH regulated gene (8), suggesting a possible inhibition of FSH signaling; however, the aromatase down-regulation may also be due to disruption of other androgen-associated ovarian signaling pathways such as the IGF system. In the present study, there is an increase in unhealthy antral AR-deficient follicles, which may have either an impaired response to a normal or diminished ovulatory LH surge. Additionally, the novel observations in the present study that reduced ovulation rates can be overcome by gonadotrophin hyperstimulation together with the probable delayed onset of the first ovulatory estrus suggested by the later onset of first litter may indicate an extraovarian defect such as a defective LH surge, but further neuroendocrine investigation is required to clarify the details of this mechanism.
The identification of X-linked genes affecting ovulation rates in sheep highlights that ovulation rates and litter size can be genetically regulated (45). Striking examples of gene dosage affecting ovulation is the Inverdale (FecX) and Boroola (FecB) mutations in sheep, whereby homozygous female carriers of FecX are sterile with underdeveloped ovaries (46), whereas heterozygote FecX carriers and both homozygote and heterozygote carriers of the FecB gene have increased ovulation rates (47, 48, 49). AR+/ female breeders were uniquely characterized in this study and found to display a reduction in CL numbers and an age-related subfertility, which was distinct from the pattern observed in the AR/. AR+/ breeders were observed to initially display similar fertility to homozygous normal (AR+/+) females; however, over time their reproductive performance grew progressively poorer so that their breeding productivity curve converged with the AR/ females toward the end of the 10-month breeding experiment. This finding suggests that haploinsufficiency of the inactivated AR creates functional partial AR deficiency with significant effects on breeding efficiency, a previously unsuspected gene dosage effect of AR on female fertility. This may be consistent with observations that genetic polymorphisms determining different AR sensitivity correspond to androgen-sensitive disorders (50, 51). For example, the polymorphic CAG trinucleotide repeat in exon 1 of the AR determines AR sensitivity (or activity) and may influence the development of PCOS (52, 53). Hence, the AR+/ female may prove to be a very useful tool in further characterization of the effects of AR deficiency in women. For example, our finding predicts that mothers of males with complete androgen insensitivity who are obligate heterozygotes for the same mutation may have curtailed reproductive function particularly at an older age.
Results from the current study showed that egg (fertilization) and early embryo viability (progression to two-cell stage) from naturally mated AR/ and AR+/ females were unaltered, supporting our hypothesis that the major physiological role for androgens in follicular dynamics is regulating late stages of follicular development and ovulation. The observed effects of androgens during the later stages of follicle growth, oocyte maturation, and ovulation (54, 55, 56, 57, 58) along with the persistent high AR expression in the OCC and granulosa cells lying in close proximity to the OCC are consistent with a paracrine role of androgens in oocyte health and ovulation (59). Kit ligand and bone morphogenetic protein 15 gene expression, which are both involved in the oocyte-granulosa cell regulatory loop, have previously been observed to be reduced in AR/ ovaries (28). In the present study, oocyte health appeared to be maintained by the observed normal growth, fertilization, and cleavage rates. However, future investigation should analyze whether the crucial oocyte-somatic cell interactions, which ensure correct signaling for key ovulatory processes such as oocyte maturation and cumulus cell expansion, are maintained because in a previous AR knockout model, cumulus cells were found to be disassociated from the oocyte in preovulatory follicles (29).
Our results clearly showed that there was no drastic effect of AR deficiency on follicle populations present within the AR/ ovaries. At diestrus follicle numbers were equivalent to that observed in the AR+/+ controls. However, this does not fully exclude difference in follicle dynamics at other stages of the estrous cycle. Despite androgens being implicated in enhancing follicle growth (60, 61), the present detailed analysis of follicle growth showed no differences. Hence, classical genomic AR-mediated actions do not appear to play essential roles in somatic cell proliferation. The overexpression of AR in estrogen receptor-ß knockout mouse ovaries is associated with high levels of follicular atresia but can be reversed by the addition of an AR antagonist (9), suggesting that AR could play a vital role in regulating granulosa cell survival and hence protecting the follicle from undergoing follicular atresia. In the present study, a significant increase in the incidence of unhealthy antral follicles within AR/ ovaries at 1012 and 26 wk of age suggests an increase in follicular atresia; however, this was not confirmed by ZPR counts or gene expression for the proapoptotic protein Bax, suggesting that follicle atresia is not the major cause of the observed reduced fertility in this model.
The normal serum levels of FSH, LH, E2, and T at diestrus remain consistent with our hypothesis of impaired late stages of follicle development and ovulation. However, taken together the high intraovarian T levels observed, especially in the youngest AR/ mice, with the present observations of poor follicle health and disrupted ovulation, suggests that ovarian androgens may initiate effects on the developing follicle by mechanisms not requiring the AR, such as T inducing maturation in mouse oocytes arrested in meiosis, independently of transcription (55). Our gene expression analysis observed no change in expression of androgen metabolizing enzymes (5
-reductase and 3
- and 3ß-HSD), indicating that the intraovarian T is unlikely to exert its effects via conversion to dihydrotestosterone, or its further 3-hydroxyated metabolites (3
- or 3ß-androstanediols), which might exert actions via an estrogen receptor. Hence, our finding supports the possibility that the high levels of T observed in the AR/ ovaries, which may be due to a reduction in aromatase, may exert long-term detrimental affects on follicle health and ovulatory processes, consistent with previous findings that treatment of rat granulosa cells with dihydrotestosterone at doses greater than 1 mg/rat inhibits LH receptor induction and hence ovulatory responses (18). Furthermore, in women with elevated levels of ovarian androgens that promote abnormal ovarian growth and development of polycystic ovaries containing follicles unable to ovulate, treatment with the AR antagonist flutamide improves fertility in some individuals, which is consistent with AR-mediating critical actions during late follicle development and ovulation (33, 62).
In summary, we have shown that a loss of classical genomic AR signaling in the ovary leads to subfertility, dysfunctional late follicle development, and a major disruption in ovulation rates. Hence, classical genomic AR-mediated actions have a key involvement in optimizing late follicle development and processes required for successful ovulation. Furthermore, this study provides a clearer understanding of the role of androgens in ovarian physiology and highlights that AR might be of significance clinically as a target gene in the treatment of androgen-associated fertility disorders such as PCOS. The discovery that AR+/ females develop age-dependent subfertility could be of significance in further characterizing AR function in women with the possibility that impaired AR signaling may contribute to a premature reduction in female fecundity.
| Acknowledgments |
|---|
| Footnotes |
|---|
Disclosure Statement: The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work. K.A.W., C.M.A., M.J., P.R.L., R.A.D., J.D.Z., and D.J.H. have nothing to disclose. P.I. previously received lecture fees from Serono Ply.
First Published Online April 26, 2007
Abbreviations: AR, Androgen receptor; Bax, Bcl-2-associated X protein; Bcl-2, B cell leukemia/lymphoma-2; CL, corpus lutea; CMV, cytomegalovirus; E2, estradiol; HSD, hydroxysteroid dehydrogenase; OCC, oocyte-cumulus complex; PCNA, proliferating cell nuclear antigen; PCOS, polycystic ovary syndrome; T, testosterone; ZPR, zona pellucida remnant.
Received February 23, 2007.
Accepted for publication April 13, 2007.
| References |
|---|
|
|
|---|
and androstenedione on follicular growth and aromatization in culture. Hum Reprod 10:27672772This article has been cited by other articles:
![]() |
K. A. Walters, K. J. McTavish, M. G. Seneviratne, M. Jimenez, A. C. McMahon, C. M. Allan, L. A. Salamonsen, and D. J. Handelsman Subfertile Female Androgen Receptor Knockout Mice Exhibit Defects in Neuroendocrine Signaling, Intraovarian Function, and Uterine Development But Not Uterine Function Endocrinology, July 1, 2009; 150(7): 3274 - 3282. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Simanainen, K. McNamara, R. A. Davey, J. D. Zajac, and D. J. Handelsman Severe Subfertility in Mice with Androgen Receptor Inactivation in Sex Accessory Organs But Not in Testis Endocrinology, July 1, 2008; 149(7): 3330 - 3338. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.A. Walters, C.M. Allan, and D.J. Handelsman Androgen Actions and the Ovary Biol Reprod, March 1, 2008; 78(3): 380 - 389. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |